Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.46 |
| ▸ | LPL | P06858 | 7/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | F11 | P03951 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29656921 | 0.89 | LIPG (0.44) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL29103279 | 0.89 | LIPG (0.44) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL22290583 | 0.89 | LIPG (0.44) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL19384526 | 0.87 | LIPG (0.43) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL31627012 | 0.87 | LPL (0.45) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL2450679 | 0.87 | LPL (0.45) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL23363514 | 0.86 | LIPG (0.42) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL29899260 | 0.86 | LPL (0.42) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL23363581 | 0.86 | LPL (0.42) | LIPGLPLAAK1HIF1ADGAT1 | |
| SCHEMBL31626924 | 0.86 | LIPG (0.44) | LIPGLPLAAK1HIF1ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | LIPG 2840/4885LPL 1522/4885AAK1 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.